Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19116131 | 0.94 | ALDH1A1 (0.54) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL7355592 | 0.90 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL10415040 | 0.87 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPK1L3MBTL1TDP1 | |
| Succinic Acid SCHEMBL29551144 | 0.85 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL4915672 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPK1L3MBTL1TDP1 | |
| SCHEMBL3726102 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL1011103 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPK1L3MBTL1TDP1 | |
| SCHEMBL10030999 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL19912955 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4EMAPK1L3MBTL1 | |
| SCHEMBL7350746 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| CN-113727966-A | Panthenol derivatives and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3887353-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2020113209-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | COMET THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | ALDH1A1 806/4885LMNA 2015/4885KDM4E 4362/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885LMNA 1722/4885KDM4E 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.